Skip to main content
. Author manuscript; available in PMC: 2011 Apr 13.
Published in final edited form as: Arch Ophthalmol. 2011 Apr;129(4):481–489. doi: 10.1001/archophthalmol.2011.48

Table 5.

Multivariate model odds ratios and 95% confidence intervals for early age-related macular degeneration (AMD), assessed from 2001–2004, among participants (<75 years) reporting high compared to low levels of sunlight exposure and consuming high compared to low intake of vitamin D from foods and supplements, assessed in1993–1998: Carotenoids in Age-Related Eye Disease Study CAREDS (n=968).

Time spent in sunlight (hours/day) < 1 hours 1 to 3 hours >3 hours P for trend*
# with AMD/# in sunlight category 49/384 75/483 15/101
Multivariate model 1.0 1.15 (0.78–1.72) 1.15 (0.59–2.15) 0.46
Total vitamin D intake from foods and supplements combined Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for trend*
Quintiles, μg/day (median (range)) 2.8 (0.4–4.5) 6.5 (>4.5–9.5) 12.2 (>9.5–14) 15.8 (>14–18) 21.4 (>18–61)
# with AMD/# in quintile 36/211 24/200 37/196 28/177 14/184
Multivariate model 1.00 0.67 (0.38–1.18) 1.09 (0.65–1.84) 0.90 (0.51–1.56) 0.41 (0.20–0.78) 0.15
Vitamin D intake from supplements, μg/day None >0 to <10 μg 10 μg >10 μg P for trend*
# with AMD/# in supplement use category 64/407 17/120 44/301 14/140
Multivariate model 1.00 0.85 (0.46–1.50) 0.89 (0.58–1.36) 0.59 (0.30–1.09) 0.60
Vitamin D intake from foods Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for trend*
Quintiles, μg/day (median (range)) 2.0 (0.4–2.7) 3.5 (>2.7–4.2) 5.0 (>4.2–5.8) 7.0 (>5.8–8.6) 10.6 (>8.6–30.4)
# AMD/# in quintile 30/206 34/198 35/201 21/189 19/174
Multivariate model 1.00 1.20 (0.69–2.08) 1.24 (0.72–2.16) 0.75 (0.41–1.37) 0.74 (0.39–1.38) 0.04
*

A P-value was obtained for the linear trend by replacing the categorical predictor with the continuous variable.

Worse eye, adjusted for age at photography, and risk factors for age-related macular degeneration (smoking pack years, iris pigmentation, family history of AMD, cardiovascular disease, diabetes, and hormone use status).